New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more
What to Expect From an Eye Injection
We know the idea of having an injection in your eye can sound scary, but for many retinal diseases, it is the only way we can deliver potentially sight-saving medicine where it
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more Why You Should Continue Your Retina Care
We know the COVID-19 pandemic has made some patients, especially those over 65 or with other risk factors, nervous about venturing out of their homes. However, maintaining your retina care, including intravitreal
read more
Ashkan Abbey, MD, Publishes Article Summarizing Highlights from American Academy of Ophthalmology Retina 2019 Subspecialty Day
Texas Retina Associates’ Ashkan Abbey, MD, recently published an article in the current issue of Retina Specialist that summarized the findings of five compelling clinical trial presentations from the American Academy of
read more